Methylene blue as a vasopressor: A meta-analysis of randomised trials

Critical Care and Resuscitation

Volumn 15, Issue 1, 2013, Pages 42-48

  Pasin, Laura ^a   Umbrello, Michele ^b   Greco, Teresa ^a   Zambon, Massimo ^a   Pappalardo, Federico ^a   Crivellari, Martina ^a   Borghi, Giovanni ^a   Morelli, Andrea ^c   Zangrillo, Alberto ^a   Landoni, Giovanni ^a,d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Maieutics Foundation   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLENE BLUE; VASOCONSTRICTOR AGENT;

ARTICLE; HUMAN; HYPOTENSION; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

HUMANS; HYPOTENSION; METHYLENE BLUE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASOCONSTRICTOR AGENTS;

MLCS; MLOWN;

EID: 84880826700     PISSN: 14412772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Moreno R, Vincent JL, Matos R, et al. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med 1999; 25: 686-96.
2. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345: 588-95.
3. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
4. Dunser MW, Ruokonen E, Pettila V, et al. Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care 2009;13: R181.
5. Levy B, Collin S, Sennoun N, et al. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Med 2010; 36: 2019-29.
6. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepin ephrine infusion in patients with septic shock. N Engl J Med 2008; 28; 358: 877-87.
7. Hollenberg SM, Cinel I. Bench-to-bedside review: nitric oxide in critical illness - update 2008. Crit Care 2009; 13: 218.
8. Cobb JP, Natanson C, Hoffman WD, et al. N omega-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J Exp Med 1992; 176: 1175-82.
9. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomised, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32: 21-30.
10. Martin W, Villani GM, Jothianandan D, et al. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther 1985; 232: 708-16.
11. Gryglewski RJ, Zembowicz A, Salvemini D, et al. Modulation of the pharmacological actions of nitrovasodilators by methylene blue and pyocyanin. Br J Pharmacol 1992; 106: 838-45.
12. Daemen-Gubbels CR, Groeneveld PH, Groeneveld AB, et al. Methylene blue increases myocardial function in septic shock. Crit Care Med 1995; 23: 1363-70.
13. Preiser JC, Lejeune P, Roman A, et al. Methylene blue administration in septic shock: a clinical trial. Crit Care Med 1995; 23: 259-64.
14. Biondi-Zoccai GG, Agostoni P, Abbate A, et al. A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol 2005; 34: 224-5.
15. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0, updated March 2011. http://handbook.cochrane.org (accessed Apr 2012).
16. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
17. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
18. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700. doi: 10.1136/bmj.b2700.
19. Salman AE, Salman MA, Saricaoglu F, et al. Pain on injection of propofol: a comparison of methylene blue and lidocaine. J Clin Anesth 2011; 3: 270-4.
20. Juffermans NP, Vervloet MG, Daemen-Gubbels CR, et al. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide 2010; 22: 275-80.
21. Sparicio D, Landoni G, Zangrillo A. Angiotensin-converting enzyme inhibitors predispose to hypotension refractory to norepinephrine but responsive to methylene blue. J Thorac Cardiovasc Surg 2004; 127: 608.
22. Sparicio D, Landoni G, Pappalardo F, et al. Methylene blue for lithium-induced refractory hypotension in off-pump coronary artery bypass graft: report of two cases. J Thorac Cardiovasc Surg 2004; 127: 592-3.
23. Koelzow H, Gedney JA, Baumann J, et al. The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. Anesth Analg 2002; 94: 824-9.
24. Maslow AD, Stearns G, Butala P, et al. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth Analg 2006; 103: 2-8.
25. Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomised, controlled study. Crit Care Med 2001; 29: 1860-7.
26. Memis D, Karamanlioglu B, Yuksel M, et al. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care 2002; 30: 755-62.
27. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004; 77: 496-9.
28. Donati A, Conti G, Loggi S, et al. Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? Crit Care Med 2002; 30: 2271-7.
29. Evora PR, Roselino CH, Schiavetto PM. Methylene blue in anaphylactic shock. Ann Emerg Med 1997; 30: 240.
30. Kwok ESH, Howes D. Use of methylene blue in sepsis: a systematic review. J Intensive Care Med 2006; 21: 359-63.
31. Shanmugam G. Vasoplegic syndrome - the role of methylene blue. Eur J Cardiothorac Surg 2005; 28: 705-10.
32. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998; 116: 973-80.
33. Cremer J, Martin M, Redl H, et al. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996; 61: 1714-20.
34. Welch G, Loscalzo J. Nitric oxide and the cardiovascular system. J Card Surg 1994; 9: 361-71.
35. Martinez-Ruiz A, Cadenas S, Lamas S. Nitric oxide signaling: classical, less classical, and nonclassical mechanisms. Free Radic Biol Med 2011; 51: 17-29.
36. Petros A, Lamb G, Leone A, et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994; 28: 34-9.
37. Klabunde RE, Ritger RC. NG-monomethyl-l-arginine (NMA) restores arterial blood pressure but reduces cardiac output in a canine model of endotoxic shock. Biochem Biophys Res Commun 1991; 178: 1135-40.
38. Wright CE, Rees DD, Moncada S. Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 1992; 26: 48-57.
39. Wolin MS, Cherry PD, Rodenburg JM, et al. Methylene blue inhibits vasodilation of skeletal muscle arterioles to acetylcholine and nitric oxide via the extracellular generation of superoxide anion. J Pharmacol Exp Ther 1990; 254: 872-6.
40. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 1993; 45: 367-74.
41. Griffith TM, Edwards DH, Lewis MJ, et al. Evidence that cyclic guanosine monophosphate (cGMP) mediates endotheliumdependent relaxation. Eur J Pharmacol 1985; 112: 195-202.
42. Ignarro LJ, Harbison RG, Wood KS, et al. Dissimilarities between methylene blue and cyanide on relaxation and cyclic GMP formation in endothelium-intact intrapulmonary artery caused by nitrogen oxide-containing vasodilators and acetylcholine. J Pharmacol Exp Ther 1986; 236: 30-6.
43. Mayer B, Brunner F, Schmidt K. Novel actions of methylene blue. Eur Heart J 1993; 14 Suppl 1: 22-6.